Investor Update: Torrent Pharmaceuticals Ltd. Q3 FY26 Performance

Torrent Pharmaceuticals Ltd. (TORNTPHARM) has demonstrated robust financial resilience and operational excellence for the quarter ended December 31, 2025. Despite marginal equity market fluctuations, the company reported a significant 26.3% year-on-year increase in Net Profit, reaching ₹635 crore. Financial Highlights The company’s growth trajectory remains strong across all key metrics: Revenue: Scaled to ₹3,303 crore, a growth of 17.6% YoY. EBITDA: Increased by 19% to ₹1,088 crore. EBITDA Margin: Improved to 32.9%, reflecting disciplined cost management and a favorable product mix. Interim Dividend: The Board has declared an interim dividend of ₹29 per share (580% of face value), payable around March 6, 2026. Segmental Performance 1. Domestic Market (India): Contributing roughly 54% of Q3 revenue, the India business grew 14% to ₹1,798 crore. Torrent continues to outperform the Indian Pharmaceutical Market (IPM), particularly in high-yield chronic and sub-chronic therapies such as Cardiac, Gastro, and Diabetes. 2. International Growth: Brazil: Recorded a standout 27% revenue surge (₹371 crore). Growth was driven by top-tier brand performance and a robust pipeline, with 60 products currently under ANVISA review. United States: Revenue grew 19% to ₹321 crore, supported by successful new product launches achieving target market shares. Germany: Revenue reached ₹304 crore (+8% YoY). While constant currency growth was hampered by third-party supply disruptions, the underlying demand remains stable. Strategic Outlook The recent "clean chit" from the USFDA and the strategic increase in the company's stake in JB Chemicals (now at 48.75%) further solidify Torrent's market position. With a strong balance sheet and consistent outperformance in core therapies, the company is well-positioned for sustained long-term value creation.